Biosig Technologies, INC Form 4 insider transactions
Interim CFO of BioSig Technologies, Ferdinand Groenewald, reports acquiring 35,000 shares of common stock and disposing of 60,000 shares in a recent transaction.
Anthony N. Amato, CEO of BioSig Technologies, acquired 23,345 shares of common stock in lieu of cash for Q4 2024 and Q1 2025 board fees.
Frederick Hrkac, a director at BioSig Technologies, acquired 23,345 shares of common stock in lieu of cash compensation for board fees.
Director Donald Browne acquired 23,345 shares of BioSig Technologies common stock in lieu of cash compensation for board fees.
Director Christopher Allen Baer acquired 23,345 shares of BioSig Technologies common stock in lieu of cash compensation for board fees.
Director Steven Eric Abelman acquired 23,345 shares of BioSig Technologies common stock in lieu of cash compensation for board fees.
BioSig Technologies CEO Anthony Amato acquired shares of common stock and options on September 11, 2024.
Director Steven Eric Abelman of BioSig Technologies, Inc. reports acquisition and disposal of common stock on July 26, 2024.
Form 4: BioSig Technologies Director Christopher Baer Acquires and Disposes of Shares in Recent Transaction
Director Christopher Allen Baer of BioSig Technologies, Inc. reports acquisition and disposal of common stock on July 26, 2024.
Director Donald Browne of BioSig Technologies, Inc. reports acquiring 30,000 shares and disposing of 80,000 shares of common stock on July 26, 2024.
Director Frederick Hrkac acquired 30,000 shares of BioSig Technologies common stock on July 26, 2024, as a grant for services.
Frederick Hrkac, a director at BioSig Technologies, reported acquiring 50,000 shares of common stock on June 7, 2024, as part of a restricted stock grant for services.
Frederick Hrkac, a director of BioSig Technologies, acquired 500,000 shares of common stock on March 1, 2024, as part of a restricted stock grant for services.